Search

Agios Pharmaceuticals Inc

Avatud

SektorTervishoid

33.83 3.96

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

32.4

Max

34.15

Põhinäitajad

By Trading Economics

Sissetulek

-1.6M

-101M

Müük

24M

45M

Aktsiakasum

-1.69

Kasumimarginaal

-225.06

Töötajad

539

EBITDA

-11M

-109M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+26.62% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

29. okt 2026

Turustatistika

By TradingEconomics

Turukapital

-191M

2B

Eelmine avamishind

29.87

Eelmine sulgemishind

33.83

Uudiste sentiment

By Acuity

50%

50%

150 / 340 Pingereas Healthcare

Agios Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 19:36 UTC

Agios Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close amid broader market volatility linked to geopolitical events.

21. aug 2026, 19:36 UTC

Agios Pharmaceuticals Inc shares are lower during Friday's session amid rising U.S. Treasury yields and ongoing geopolitical tensions. No specific news was identified.

20. aug 2026, 20:01 UTC

News

Agios Pharmaceuticals Inc. shares are lower today, driven by a significant downturn in the Biotechnology sector and heightened trading volume.

19. aug 2026, 20:06 UTC

Agios Pharmaceuticals shares are higher today, though they pulled back from a session high. Broader market sentiment may be influenced by rising cryptocurrency values.

18. aug 2026, 22:51 UTC

Agios Pharmaceuticals shares are lower in after-market hours, amid broader negative sentiment linked to rising sovereign bond yields and persistent inflation risks.

17. aug 2026, 19:41 UTC

News

Agios Pharmaceuticals shares are rising as Cantor Fitzgerald maintains an Overweight rating ahead of the November 1 PDUFA date for mitapivat.

14. aug 2026, 19:46 UTC

Agios Pharmaceuticals Inc shares are higher today, though no specific news explains the movement. Earlier, shares peaked before dipping later in the session.

12. aug 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher today amid unusually high trading volume. The stock has gained significantly since Tuesday's close.

11. aug 2026, 19:26 UTC

Agios Pharmaceuticals Inc shares are higher today, with no specific news driving the move. Market focus remains on upcoming U.S. inflation reports.

10. aug 2026, 21:01 UTC

Agios Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

6. aug 2026, 19:32 UTC

Agios Pharmaceuticals shares are higher today, continuing an upward trend since Wednesday. The stock peaked earlier in the session before a slight pullback.

5. aug 2026, 19:56 UTC

News

Agios Pharmaceuticals is under investigation regarding its decision on tebapivat, contributing to lower trading activity today amid ongoing investor concerns.

4. aug 2026, 20:02 UTC

Agios Pharmaceuticals Inc shares are higher today amid broader market gains, supported by falling crude oil prices and comments on potential peace talks with Iran.

3. aug 2026, 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31. juuli 2026, 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30. juuli 2026, 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29. juuli 2026, 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28. juuli 2026, 20:02 UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27. juuli 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24. juuli 2026, 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22. juuli 2026, 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21. juuli 2026, 19:01 UTC

News
Event
Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Võrdlus sarnastega

Hinnamuutus

Agios Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

26.62% tõus

12 kuu keskmine prognoos

Keskmine 41.33 USD  26.62%

Kõrge 55 USD

Madal 31 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Agios Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

6

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

150 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat